SCHEMBL2845009

SCHEMBL2845009

COc1cc(C)cc(-c2c(F)cccc2Br)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.41
CYP1A2 P05177 2/20 0.40
CYP2C19 P33261 2/20 0.40
CYP1A1 P04798 1/20 0.40
CYP2E1 P05181 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C8 P10632 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2A6 P11509 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP4B1 P13584 1/20 0.40
CYP2B6 P20813 1/20 0.40
CYP3A5 P20815 1/20 0.40
CYP2A7 P20853 1/20 0.40
CYP3A7 P24462 1/20 0.40
CYP2F1 P24903 1/20 0.40
CYP2C18 P33260 1/20 0.40
CYP2J2 P51589 1/20 0.40
CYP4F2 P78329 1/20 0.40
CYP4F8 P98187 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2845729 0.91 CYP1A1 (0.48) CYP1A2CYP2C19CYP1A1CYP2E1CYP3A4
SCHEMBL2847105 0.83 DYRK1A (0.45) CYP1A2CYP2C19CYP1A1CYP2E1CYP3A4
SCHEMBL2850934 0.81 ACHE (0.39) ACHETP53ALDH1A1MAPK1SMN1; SMN2
SCHEMBL1865690 0.77 CSNK1E (0.43) ACHETP53ALDH1A1MAPK1SMN1; SMN2
SCHEMBL4919253 0.77 TTR (0.40) ACHECYP1A2CYP2C19CYP3A4CYP2C9
SCHEMBL10177298 0.74 ABL1 (0.51) ACHECYP1A2CYP2C19CYP1A1CYP2E1
SCHEMBL29000156 0.72 ACHE (0.43) ACHECYP1A2CYP2C19CYP2D6CYP2C9
SCHEMBL18970413 0.71 CYP1A1 (0.58) ACHECYP1A2CYP2C19CYP1A1CYP2E1
SCHEMBL2849568 0.71 CYP1A1 (0.48) CYP1A2CYP2C19CYP1A1CYP2E1CYP3A4
SCHEMBL2952197 0.70 ALDH1A1 (0.53) ACHECYP1A2CYP2C19CYP1A1CYP2E1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007117482-A2 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2007-10-18 WO claimed
US-20100179109-A1 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. 2010-07-15 US disclosed
US-20100130471-A1 Renin Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-05-27 US disclosed
US-20090275581-A1 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. 2009-11-05 US disclosed
US-20090264428-A1 Renin Inhibitors VITAE PHARMACEUTICALS, INC. 2009-10-22 US disclosed
EP-2010488-A2 RENIN INHIBITORS Vitae Pharmaceuticals, Inc. (US) 2009-01-07 EP disclosed
WO-2008124582-A1 RENIN INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-10-16 WO disclosed
WO-2007117482-A2 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2007-10-18 WO disclosed
WO-2007117559-A2 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179109-A1 RENIN INHIBITORS REN, ACE, AGTR1 ACHE 221/4885CYP1A2 2490/4885CYP2C19 2439/4885
US-20090275581-A1 RENIN INHIBITORS REN, ACE, SERPINB1 ACHE 223/4885CYP1A2 2290/4885CYP2C19 1224/4885
US-20090264428-A1 Renin Inhibitors REN, ACE, SERPINB1 ACHE 233/4885CYP1A2 1699/4885CYP2C19 1258/4885
US-20100130471-A1 Renin Inhibitors ACE, REN, DNPEP ACHE 262/4885CYP1A2 3780/4885CYP2C19 3550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.